Development of a DNA-MVA/HIVA vaccine for Kenya.

Journal article

Without going into the details of the devastation that human immunodeficiency virus (HIV) infection causes especially in the developing world, the best hope for changing the course of this epidemic is development of a safe, effective, accessible prophylactic HIV vaccine. While the inaccessibility of potentially neutralising epitopes on primary HIV isolates has hampered the development of envelope-based vaccines, there is a number of new potent technologies capable of inducing high levels of c...

Expand abstract

Authors: Hanke, T; Mcmichael, A; Mwau, M; Wee, E; Ceberej, I

• Publication status: Published
• Journal: Vaccine
• Volume: 20
• Issue: 15
• Pages: 1995-1998
• Publication date: 2002-05-01
• DOI: 10.1016/s0264-410x(02)00085-3
• EISSN: 1873-2518
• ISSN: 0264-410X
• Language: English
• Keywords: Vaccines, Synthetic; Vaccinia virus; Clinical Trials, Phase I as Topic; CD4-Positive T-Lymphocytes; Humans; Epitopes; HIV Antibodies; Mice; Kenya; Viral Vaccines; Animals; Risk Factors; Simian immunodeficiency virus; Vaccination; CD8-Positive T-Lymphocytes; HIV-1; AIDS Vaccines; Safety; Cohort Studies; Vaccines, DNA; Macaca mulatta; Immunization, Secondary; HIV Core Protein p24; Drug Design